Indication
Ductal Carcinoma
1 clinical trial
2 products
Clinical trial
A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2020-09-20
Product
Talimogene laherparepvecProduct
Paclitaxel